Labcorp Enhances Cancer Diagnostics with New Liquid Biopsy Solutions
Labcorp Enhances Cancer Diagnostics with New Liquid Biopsy Solutions
In a groundbreaking expansion, Labcorp, a preeminent player in the realm of laboratory services, has made significant strides in precision oncology. The company recently introduced two innovative solutions aimed at improving cancer diagnostics and treatment pathways: Labcorp Plasma Detect and PGDx elio plasma focus Dx. These advancements are set to provide oncologists with essential tools to better assess and manage cancer patients, particularly those diagnosed with stage III colon cancer.
Advanced Solutions for Oncology
Labcorp Plasma Detect has been developed specifically to address the challenge of assessing the risk of recurrence in patients with stage III colon cancer, a group known for its nearly 30% recurrence rate within five years. Utilizing cutting-edge whole-genome sequencing (WGS) techniques, this blood-based test intricately detects circulating tumor DNA (ctDNA), serving as a key indicator of molecular residual disease (MRD). Understanding MRD is vital because patients flagged as MRD-positive post-treatment tend to face a significantly higher risk of cancer returning, along with a poorer prognosis. The insights gleaned from Labcorp's test are crucial, particularly as they can uncover risks that conventional diagnostic methods might overlook.
The noteworthy features of Labcorp Plasma Detect include:
- - It is Labcorp’s first MRD solution designed for direct clinical use, offering oncologists invaluable insights for recurrence risk stratification.
- - Initially launched for biopharma applications in 2024, it leverages proprietary bioinformatics to detect ctDNA to an impressive limit of detection of 0.005%.
- - Results from the test are returned to oncologists approximately 14 days after sample submission, and follow-up monitoring could yield results within just seven days.
- - Current research into its application spans over 10 clinical studies across various cancer types, ensuring the test’s efficacy and reliability.
PGDx elio Plasma Focus Dx
The second solution, PGDx elio plasma focus Dx, has gained attention as the first-ever pan-solid tumor liquid biopsy test to receive De Novo authorization from the U.S. Food and Drug Administration (FDA). This innovative assay provides oncologists with validated capabilities to evaluate different solid tumors, streamlining the process for identifying patients who may benefit from targeted therapies.
Notable aspects of PGDx elio plasma focus Dx include:
- - It operates on a kitted model, offering clinical laboratories and healthcare facilities autonomy over patient specimens and data, crucial for ongoing research and management.
- - As an FDA-authorized assay, it allows for swift on-site verification without the need for full validation, facilitating rapid deployment within healthcare settings.
- - Once in use, this scalable genomic test delivers actionable findings within a timely 4-to-5-day turnaround period, enhancing the decision-making capacity of oncologists.
- - Moreover, the PGDx elio platform supports seamless integration with existing tissue testing processes, driving efficiency and comprehensive genomic profiling within clinical workflows.
Commitment to Innovation
Dr. Shakti Ramkissoon, Labcorp’s vice president and medical lead for oncology, emphasized the company’s commitment to transforming cancer diagnostics. “Labcorp is dedicated to providing oncologists with innovative solutions that enable precise, timely, and personalized treatment decisions,” he stated. He also expressed excitement about the role these new products will play in enhancing patient outcomes across various cancer types.
Labcorp intends to showcase these advancements at the American Association for Cancer Research (AACR) 2025 Annual Meeting, where further clinical data on their applications will be presented. Attendees and interested parties can look forward to engaging with Labcorp to explore these transformative technologies in cancer care.
For those eager to learn more about Labcorp's oncology solutions and advancements in cancer diagnostics, additional information can be found on their official website. Furthermore, the company continues to emphasize its mission of providing unparalleled support and insights that empower healthcare providers and improve patient health outcomes around the globe.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.